Prognostic factors and outcome in relapsed multiple myeloma after nonmyeloablative allo-SCT: a single center experience

M. C. Minnema, S. van Dorp, N. W. C. J. van de Donk, F. Schouten, M. J. Kersten, J. L. L. M. Coenen, H. Schouten, S. Zweegman, R. Schaafsma, H. M. Lokhorst

Research output: Contribution to journalArticleAcademicpeer-review

6 Citations (Scopus)


For relapsed multiple myeloma (MM) patients, allo-SCT is a possible treatment option, but recent data obtained using a nonmyeloablative (NMA) conditioning regimen are scarce. We retrospectively collected data from 38 relapsed MM patients who received a NMA allo-SCT from October 2001 to January 2008. In total, 18 patients (48%) were transplanted using a matched unrelated donor. The median follow-up is 2.3 years. In 16 patients (42%) the response improved and eight patients (21%) were rapidly progressive within 6 months after allo-SCT. In total, 15 patients (39%) were in CR after allo-SCT. The median PFS was 1.4 years (range, 0.1-4.9), and having a CR after allo-SCT or having chronic GVHD resulted in longer PFS. Median OS was 3.1 years (range, 0.2-7.2) and again having a CR after allo-SCT or chronic GVHD was associated with a better OS. Six patients (16%) have died from treatment-related diseases. These results indicate that NMA allo-SCT is a treatment option in relapsed MM patients and that results may be improved by strategies that enhance the CR rate after allo-SCT. Bone Marrow Transplantation (2011) 46, 244-249; doi: 10.1038/bmt.2010.101; published online 19 April 2010
Original languageEnglish
Pages (from-to)244-249
JournalBone marrow transplantation
Issue number2
Publication statusPublished - 2011

Cite this